Finance entity
earnings is the sole category represented across all 1 tracked stories. AI-powered innovations is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window.
Last mentioned: Aug 1, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
earnings is the sole category represented across all 1 tracked stories. AI-powered innovations is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window. Their average consequence score of 6 runs above the beat's 5.7 for that window. Diagnosis & Treatment appears in 1 tracked Finance story from August 1, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 25 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Diagnosis & Treatment. Shared-story counts are live from our verified record — not editorial picks.
Royal Philips beat margin expectations in Q2 with a 16.4% adjusted EBITA margin, boosted by a one-off US tariff refund, and raised its full-year profitability and free cash flow guidance, while reiterating 4% sales growth target.
Diagnosis & Treatment is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
